Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

25.68 -0.54

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

25.53

Maximum

25.72

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+53.05% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

737M

2.8B

Előző nyitás

26.22

Előző zárás

25.68

Hangulat hírek alapján

By Acuity

38%

62%

77 / 339 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 18. 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

2026. szept. 18. 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

2026. szept. 18. 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

2026. szept. 18. 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

2026. szept. 18. 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

2026. szept. 18. 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

2026. szept. 18. 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

2026. szept. 18. 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

2026. szept. 18. 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

2026. szept. 18. 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

2026. szept. 18. 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

2026. szept. 18. 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

2026. szept. 18. 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

2026. szept. 18. 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

2026. szept. 18. 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

2026. szept. 18. 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

2026. szept. 18. 23:01 UTC

News

Kimberly-Clark Corp plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns, with shares modestly higher in after-market trading.

2026. szept. 18. 23:01 UTC

Social Media
News

Accenture PLC announced a $1 billion partnership with Anthropic to enhance AI evaluation capabilities, leading to a sharp advance in shares during after-market hours.

2026. szept. 18. 23:01 UTC

News

Bitcoin is sharply higher, trading well above its previous close amid a rally in the cryptocurrency market, driven by strong investor sentiment and recent Fed announcements.

2026. szept. 18. 23:01 UTC

News

Ethereum is advancing sharply, continuing its upward trajectory alongside a broader cryptocurrency rally, despite earlier pulling back from a session high.

2026. szept. 18. 23:01 UTC

News

Ethereum is advancing sharply, remaining significantly higher since Thursday's close, as the cryptocurrency market rallies alongside Bitcoin surpassing $81k.

2026. szept. 18. 23:01 UTC

News

Sharply higher amid strong investor sentiment and Fed announcements.

2026. szept. 18. 23:01 UTC

News
Social Media

Wendy's Co shares are trading modestly higher in after-market hours despite concerns over Meritage Hospitality Group's Chapter 11 bankruptcy filing affecting 314 locations.

2026. szept. 18. 22:51 UTC

News

Lockheed Martin Corp receives an $871.2 million contract modification for F-35 support, contributing to a modest after-market hours gain.

2026. szept. 18. 22:51 UTC

News

Hf Foods Group Inc. has terminated its $100 million at-the-market equity offering program, leading to a sharp decline in after-market trading.

2026. szept. 18. 22:01 UTC

News

Simply Good Foods Co is facing a securities fraud class action lawsuit, contributing to a modest decline in after-market trading following concerns over OWYN's sales performance.

2026. szept. 18. 21:41 UTC

News

Amneal Pharmaceuticals received FDA approval for its lanreotide injection, launching the product immediately, driving shares higher in after-market hours.

2026. szept. 18. 21:03 UTC

Macro News
News
Macro Event

The Bank of Japan raised its key interest rate to 1.25%, boosting the USD/JPY pair, which is trading higher above Thursday's close.

2026. szept. 18. 21:01 UTC

News

Navient Corp is seeing a modest increase in after-market trading, reflecting routine performance and placing the price around the middle of its one-month range.

2026. szept. 18. 21:01 UTC

News
Macro Event
Correlated Moves

The Bank of Japan raised its key short-term interest rate to 1.25%, causing GBP/JPY to trade modestly higher, though still below its 20-day moving average.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

53.05% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 39.333 USD  53.05%

Magas 45 USD

Alacsony 36 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

3 ratings

3

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

77 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.